Learn more

METABOLEX INC

Overview
  • Total Patents
    336
  • GoodIP Patent Rank
    216,727
About

METABOLEX INC has a total of 336 patent applications. Its first patent ever was published in 1990. It filed its patents most often in United States, WIPO (World Intellectual Property Organization) and EPO (European Patent Office). Its main competitors in its focus markets pharmaceuticals, organic fine chemistry and biotechnology are HUBEI BIO PHARMACEUTICAL INDUSTRIAL TECH INSTITUTE INC, BASILEA PHARMACEUTICA AG and DART NEUROSCIENCE LLC.

Patent filings per year

Chart showing METABOLEX INCs patent filings per year from 1900 to 2020

Top inventors

# Name Total Patents
#1 Chen Xin 107
#2 Zhao Zuchun 103
#3 Ma Jingyuan 90
#4 Song Jiangao 65
#5 Rabbat Christopher J 61
#6 Johnson Jeffrey D 59
#7 Nashashibi Imad 59
#8 Zhu Yan 49
#9 Cheng Peng 48
#10 Novack Aaron 43

Latest patents

Publication Filing date Title
US2014206892A1 DCC mediated coupling for halofenate manufacture
US2013109734A1 GPR120 receptor agonists and uses thereof
WO2013032939A1 Bicyclic agonists of gpr131 and uses thereof
WO2012174164A2 Agonists of gpr131 and uses thereof
CN104066427A Methods for treating hyperuricemia in patients with gout using halofenate or halofenic acid and a second urate-lowering agent
BR112012032248A2 5-ethyl-2- {4 - [- 4- (-4-tetrazol-1-yl-phenoxymethyl) -thiazol-2-yl] -piperidin-1-yl} -pyrimidine compositions
CA2775840A1 Substituted tetrazol-1-yl-phenoxymethyl-thiazol-2-yl-piperidinyl-pyrimidine salts
US2011160222A1 Modulators of glucose homeostasis for the treatment of diabetes and metabolic disorders
TW201200505A GPR120 receptor agonists and uses thereof
WO2011159297A1 Gpr120 receptor agonists and uses thereof
CA2740874A1 Use of ppar.gamma.agonists to reduce small dense ldl particles
CN102203074A Aryl GPR119 agonists and uses thereof
KR20100134659A Oxymethylene aryl compounds and uses thereof
WO2009046371A1 Methods of treating metabolic diseases
KR20100033419A N-azacyclic substituted pyrrole, pyrazole, imidazole, triazole and tetrazole derivatives as agonists of the rup3 or gpr119 receptor for the treatment of diabetes and metabolic disorders
TW200833688A Heterocyclic receptor agonists for the treatment of diabetes and metabolic disorders
US2009054475A1 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine
ZA200803329B Process for the stereoselective preparation of (-)-halofenate and intermediates thereof
US2007073082A1 Resolution of α-(phenoxy) phenylacetic acid derivatives with naphthyl-alkylamines
US2007072858A1 Process for the stereoselective preparation of (−)-halofenate and derivatives thereof